EFFICACY AND SAFETY OF ONCE-DAILY INDACATEROL/MOMETASONE COMPARED WITH TWICE-DAILY SALMETEROL/FLUTICASONE IN PATIENTS WITH MODERATE TO VERY SEVERE COPD

被引：0
|
作者：
Kirsten, Anne-Maria [1 ]
Richard, Alexia [2 ]
Tanase, Ana-Maria [2 ]
Cao Weihua [3 ]
Hosoe, Motoi [2 ]
Hederer, Bettina [2 ]
机构：
[1] German Ctr Lung Res, Pulm Res Inst, Lung Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany
[2] Novartis Pharma AG, Basel, Switzerland
[3] Nova Pharmaceut Corp, Madison, NJ USA
来源：
THORAX | 2014年 / 69卷
关键词：
D O I：
10.1136/thoraxjnl-2014-206260.379
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P251
引用
收藏
页码：A187 / A187
页数：1
相关论文
共 50 条
  • [1] A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
    Agusti, Alvar
    de Teresa, Luis
    De Backer, Wilfried
    Zvarich, Michael T.
    Locantore, Nicholas
    Barnes, Neil
    Bourbeau, Jean
    Crim, Courtney
    EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (03) : 763 - 772
  • [2] Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study
    Korn, Stephanie
    Kerwin, Edward
    Atis, Sibel
    Amos, Carolynn
    Owen, Roger
    Lassen, Cheryl
    RESPIRATORY MEDICINE, 2011, 105 (05) : 719 - 726
  • [3] Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison
    Kornmann, O.
    Dahl, R.
    Centanni, S.
    Dogra, A.
    Owen, R.
    Lassen, C.
    Kramer, B.
    EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (02) : 273 - 279
  • [4] Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD
    Salvi, Sundeep
    Kumar, Anand
    Agrawal, Sumit
    Leuva, Amrutlal
    Shukla, Vineet
    Deshpande, Shrikant
    Balamurugan, Santhalingum
    Singh, Ajeet
    Tikkiwal, Sharad
    Gupta, Sandeep
    Sawant, Sandesh
    Vaidya, Abhijit
    Gogtay, Jaideep
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [5] Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study
    Fogel, Robert
    Chapman, Kenneth R.
    Vogelmeier, Claus F.
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Whelan, Sarah
    Clerkin, Karyn
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [6] A Comparison of the Efficacy of Once-Daily Fluticasone Furoate/Vilanterole with Twice-Daily Fluticasone Propionate/Salmeterol in Elderly Asthmatics
    Ishiura, Yoshihisa
    Fujimura, Masaki
    Shiba, Yasutaka
    Ohkura, Noriyuki
    Hara, Johsuke
    Abo, Miki
    Kasahara, Kazuo
    DRUG RESEARCH, 2018, 68 (01) : 38 - 44
  • [7] A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome
    Ishiura, Yoshihisa
    Fujimura, Masaki
    Shiba, Yasutaka
    Ohkura, Noriyuki
    Hara, Johsuke
    Kasahara, Kazuo
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 35 : 28 - 33
  • [8] Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients
    Dransfield, Mark T.
    Feldman, Gregory
    Korenblat, Phillip
    LaForce, Craig F.
    Locantore, Nicholas
    Pistolesi, Massimo
    Watkins, Michael L.
    Crim, Courtney
    Martinez, Fernando J.
    RESPIRATORY MEDICINE, 2014, 108 (08) : 1171 - 1179
  • [9] ADHERENCE WITH ONCE-DAILY FLUTICASONE FUROATE/VILANTEROL COMPARED TO TWICE-DAILY BUDESONIDE/FORMOTEROL OR FLUTICASONE PROPIONATE/SALMETEROL IN ASTHMA
    Averell, C.
    Stanford, R.
    Laliberte, F.
    Wu, J.
    Germain, G.
    Duh, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S39 - S39
  • [10] Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥ 1 exacerbation in the previous year: The FLAME study
    Wedzicha, Jadwiga
    Vogelmeier, Claus F.
    Ayers, Tim
    FowlerTaylor, Angel
    Thach, Chau
    Olsson, Petter
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
12345